Clinical trial
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
NCT04418154
Study timeline
Study start (actual)2020-06-09Date precision: day
Registry last updated2024-05-21
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Interventions
epirubicin hydrochlorideDRUG · verified · RxNorm: epirubicin hydrochloride
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
ToripalimabDRUG · verified · RxNorm: toripalimab
Sponsors & collaborators
Fudan Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04418154 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.